Cyclin dependent kinase 2

Bortezomib was purchased from LC Laboratories (Woburn, MA, USA). For in vitro studies, the drug was reconstituted in dimethyl sulfoxide (DMSO) at a stock concentration of 1 mM and stored at −80°C. The small‐molecule inhibitors MKC3946 and GSK2606414 were bought from MedChemExpress (Monmouth Junction, NJ, USA). The stock solution for MKC3946 and GSK2606414 was prepared in DMSO at a concentration of 10 mM and stored at −20°C. The antibodies against p21^Cip1, p27^Kip1, X‐box‐binding protein 1 (Xbp1s), activating transcription factor 6 (Atf6), 78 kDa glucose‐regulated protein (Grp78), C/EBP homologous protein (Chop), cyclin D3, cyclin E1, cyclin‐dependent kinase 2 (CDK2), cyclin‐dependent kinase 4 (CDK4) and β‐actin were obtained from Proteintech (Wuhan, Hubei, China), and the antibody against activating transcription factor 4 (Atf4) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). All other chemicals were obtained from Sigma‐Aldrich (Burlington, MA, USA) unless otherwise specified.

M. oleifera seeds were purchased from Yunnan Tianyou Technology Development Co., Ltd.; Dehong, Yunnan, China. Antibodies against caspase-3, Bax, Bcl-2, and cyclin E were purchased from Shenyang Wanclass Biotechnology Co., Ltd., Shenyang, China. C-Jun N-terminal kinase (JNK) and phosphorylated C-Jun N-terminal kinase (p-JNK)-specific antibodies were purchased from Jiangsu Qiaoke Biological Research Center Co., Ltd., Jiangsu, China. Cyclin D1, cyclin A2, and cyclin-dependent kinase 2 (CDK2) antibodies were purchased from Proteintech Group, Inc., Wuhan, China, while β-Tubulin and GAPDH antibodies were obtained from Abcam Plc, Cambridgeshire, UK.